apomorphine hydrochloride

Also found in: Dictionary, Thesaurus, Encyclopedia.

apomorphine hydrochloride

APO-go (UK), Apokyn

Pharmacologic class: Dopaminergic, dopamine-receptor agonist

Therapeutic class: Antiparkinsonian

Pregnancy risk category C


Unclear. May stimulate postsynaptic dopamine D2-type receptors in caudate-putamen of brain.


Ampules: 10 mg/ml in 2- and 3-ml cartridges

Indications and dosages

Acute intermittent treatment of hypomobility and "off" ("end-of-dose wearing off" and unpredictable "on/off") episodes associated with Parkinson's disease

Adults: 0.2-ml (2-mg) test dose injected subcutaneously during "off" state in setting where medical personnel can monitor blood pressure. If patient tolerates test dose, give 0.2 ml subcutaneously p.r.n. to treat "off" episodes no sooner than 2 hours after previous dose. Establish dosage based on tolerance and efficacy; increase in 0.1-ml (1 mg) increments, usually to 0.3 to 0.4 ml. Maximum dosage, 0.6 ml up to five times daily.

Patient who tolerates but doesn't respond to test dose may receive 0.4 ml (4 mg) at next observed "off" period, but no sooner than 2 hours after initial 0.2-ml test dose. If patient tolerates 0.4-ml test dose, give starting dosage of 0.3 ml (3 mg) p.r.n. to treat "off" episodes. If needed, increase in increments of 0.1 ml every few days on outpatient basis.

If patient doesn't tolerate 0.4-ml test dose, 0.3-ml test dose may be given during separate "off" period no sooner than 2 hours after 0.4-ml test dose.

If patient tolerates 0.3-ml test dose, starting dosage should be 0.2 ml p.r.n. to treat existing "off" episodes. If needed and if patient tolerates 0.2-ml dose, dosage can be increased to 0.3 ml after several days; in this case, it ordinarily shouldn't be increased to 0.4 ml on outpatient basis.

Dosage adjustment

• Mild or moderate renal impairment


• Hypersensitivity to drug or its components
• Concurrent use of 5-hydroxytryptamine3 (5-HT3) antagonists (such as alosetron, dolasetron, granisetron, ondansetron, palonosetron)


Use cautiously in:
• renal or hepatic impairment
• pregnant or breastfeeding patients
• children (safety and efficacy not established).


• If prescribed, give trimethobenzamide (antiemetic) for 3 days before starting apomorphine and continuing throughout therapy.
• Give only by subcutaneous injection.

Don't give I.V. because this may cause serious adverse events, such as I.V. crystallization of apomorphine, leading to thrombus formation and pulmonary embolism.
• Titrate dosage based on efficacy and patient tolerance.
• Check supine and standing blood pressure before giving test dose and 20, 40, and 60 minutes after. If patient experiences clinically significant orthostatic hypotension in response to test dose, don't give drug.

Adverse reactions

CNS: drowsiness, somnolence, dizziness, hallucinations, confusion, syncope, dyskinesias

CV: orthostatic hypotension, chest pain, chest pressure, angina, cardiac valvulopathy

EENT: rhinorrhea

GI: nausea, vomiting, retroperitoneal fibrosis

GU: priapism

Respiratory: pulmonary infiltrates, pleural effusion, pleural thickening

Other: yawning, edema of extremities, injection site reactions, abuse potential, allergic reactions


Drug-drug.Antihypertensive agents, vasodilators: increased incidence of hypotension, myocardial infarction, serious pneumonia, serious falls, bone and joint injuries

Dopamine antagonists: decreased apomorphine efficacy

5-HT3 antagonists: profound hypotension

Drug-behaviors.Alcohol use: additive drowsiness and somnolence

Patient monitoring

• Monitor for serious cardiovascular and respiratory adverse reactions.
• Monitor for unexpected somnolence, which may interfere with daily activities.

Patient teaching

• Instruct patient to take drug as described in patient instruction leaflet.
• Make sure patient knows that dosages are in milliliters, not milligrams.
• Instruct patient to rotate injection site.
• Inform patient that drug may cause hallucinations and unexpected sleepiness.
• Tell patient that drug may cause blood pressure to drop. Caution him to rise slowly from sitting or lying position.
• Urge patient to consult prescriber before taking other drugs.
• Caution patient not to use alcohol during therapy.
• Advise patient to avoid driving and other hazardous activities until drug effects are known.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

ap·o·mor·phine hy·dro·chlor·ide

(ap'ō-mōr'fēn hī'drō-klōr'īd),
A derivative of morphine used as an emetic by the parenteral route of administration.

apomorphine hydrochloride

A grayish white powder that becomes green on exposure to water or air. An emetic, it was formerly used to treat oral overdoses. In small doses it may be used as an expectorant.
See also: apomorphine
Mentioned in ?
References in periodicals archive ?
examines applications of Apomorphine Hydrochloride and its consumers
considers Apomorphine Hydrochloride current market prices
The Company utilizes its proprietary STA-T(TM) process to administer intranasally for systemic effect a portfolio of drugs for indications that are mediated through the central nervous system, including scopolamine hydrobromide for the prevention and treatment of motion sickness, apomorphine hydrochloride for the treatment of sexual dysfunction, morphine for treatment of moderate-to-severe pain, including breakthrough pain, and butorphanol tartrate for treatment of migraine pain.
Nasdaq: NSTK) plans to commence clinical efficacy studies of an intranasal version of apomorphine hydrochloride, a promising drug for treatment of erectile dysfunction later this year.
The report indicates that apomorphine hydrochloride administered sub-lingually could achieve $500 million in sales by 2002.